TMB and BRAF mutation status are independent predictive factors in stage IIIC/D/IV melanoma patients receiving adjuvant PD-1 antibodies. Overall survival in patients who received checkpoint inhibitors ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results